31 results about "Th1 immune response" patented technology

The invention relates to methods and products for inducing an immune response using immunostimulatory nucleic acids. In particular the immunostimulatory nucleic acids preferentially induce a Th2 immune response. The invention is useful for treating and preventing disorders associated with a Th1 immune response or for creating a Th2 environment for treating disorders that are sensitive to Th2 immune responses.

Microparticles with adsorbent surfaces, methods of making such microparticles, and uses thereof, are disclosed. The microparticles comprise a polymer, such as a poly(α-hydroxy acid), a polyhydroxy butyric acid, a polycaprolactone, a polyorthoester, a polyanhydride, and the like, and are formed using cationic, anionic, or nonionic detergents. The surface of the microparticles efficiently adsorb biologically active macromolecules, such as DNA, polypeptides, antigens, and adjuvants. Also provided are compositions of an oil droplet emulsion having a metabolizable oil and an emulsifying agent. Immunogenic compositions having an immunostimulating amount of an antigenic substance, and an immunostimulating amount of an adjuvant composition are also provided. Methods of stimulating an immune response, methods of immunizing a host animal against a viral, bacterial, or parasitic infection, and methods of increasing a Th1 immune response in a host animal by administering to the animal an immunogenic composition of the microparticles, and / or microemulsions of the invention, are also provided.

This invention relates to methods of using a Listeria vaccine vector to induce a Th1 immune response in subjects having persistent Th2 immune response profiles.

The present invention relates to modulating the nature and / or level of an immune response to a molecule. In particular, the invention relates to effecting an increase in the TH1 immune response to molecules such as, but not limited to, antigens or immunogens. The invention also relates to reducing a TH2 immune response to molecules. More particularly, the invention relates to altering the level of TH1- and TH2-associated immunoglobulins, the level of proliferation of TH1- and TH2-associated cytokines, and the level of proliferation of TH1 and TH2 cells.

The present invention relates to modulating the nature and / or level of an immune response to a molecule. In particular, the invention relates to effecting an increase in the TH1 immune response to molecules such as, but not limited to, antigens or immunogens. The invention also relates to reducing a TH2 immune response to molecules. More particularly, the invention relates to altering the level of TH1- and TH2-associated immunoglobulins, the level of proliferation of TH1- and TH2-associated cytokines, and the level of proliferation of TH1 and TH2 cells.

The invention discloses a pneumococcus conjugated vaccine. The conjugate vaccine is a conjugate vaccine prepared by connecting a multivalent pneumococcus polysaccharide with two or more carrier proteins through a linker, wherein the linker is magnetic nanoparticles. The preparation method of the pneumococcus conjugated vaccine comprises the following step: coupling the multivalent pneumococcus polysaccharide and two or more carrier proteins with the nanoparticles respectively. The pneumococcus conjugated vaccine provided by the invention is simple in preparation process; by adopting the pneumococcus conjugated vaccine taking the nanoparticles as the linker, the Th1 immune response of a mouse and the immunity persistence, specificity and affinity of a polysaccharide specific antibody can be enhanced, and the mouse can be induced to produce a rotavirus antibody; the pneumococcus conjugated vaccine has the prevention effects of two kinds of vaccines, so that the pneumococcus conjugated vaccine has a very wide application prospect.

The invention relates to a mucosal immunoadjuvant inducing Th1 immune response. A bioinformatics technology is applied in the invention, the spatial conformation of a ricin B-chain monoclonal anti-3E1 and Ricin-B compound which has obtained a Chinese invention patent is determined through the action of an antibody-antigen compound, and a molecular stimulation technology is utilized to reasonably determine four Ricin B identifying active regions of 3E1 and derive four nucleotide sequences. Four GFP-nRTB fusion proteins are obtained through a molecular cloning technology. Results of experiments that the four proteins are used to immunize BALB / C mice through a sublingual way three times show that a P1-GFP protein in the four proteins excites Th1 immune response, and a high-level IgG2a antibody is generated. The capability and the possible molecular mechanism of the targeting GFP mucosal immune response of the P1-GFP protein are discussed. The mucosal immunoadjuvant inducing Th1 immune response, which is screened through the above scheme, can be used for preparing vaccines, immunomodifiers or treatment medicines.

Disclosed are compounds for use in modulating immune responses. More particularly, the present invention discloses oligomeric forms of PD-L2 for use in modulating Th1 immune responses. The compounds of the present invention find utility in a range of Th1-mediated disorders including pathogenic infections and hyperproliferative disorders.

The present invention relates to compositions and methods for the prevention and treatment of neurodegenerative diseases, such Alzheimer's disease, that are caused by misfolding, aggregating proteins. The compositions and methods of the present invention comprise a vaccine formulation comprising an antigen selected from the group consisting of i) amyloid-β or a peptide that has in its amino acid sequence part of the amyloid-β amino acid sequence, ii) hyperphosphorylated tau protein or one of its hyperphoshorylated peptides, or iii) a combination of antigens derived from groups i) and ii) and that are formulated with a non-acylated or deacylated, natural or synthetic, bidesmosidic triterpene glycoside carrying an aldehyde or ketone group, which acts as an adjuvant or immune agonist. These vaccine formulations are capable of stimulating a Th2 immunity or antibody response against antigens such as amyloid-β and tau derived antigens, but not a Th1 immune response.

The invention discloses a tuberculosis gene vaccine based on T cell epitopes, wherein a full-length gene, embedded with four T cell epitope polypeptide genes which come from mycobacterium tuberculosis antigen, of mycobacterium tuberculosis heat shock protein is inserted into a vector. The invention also discloses a method for preparing the vaccine, which comprises the following steps: four T cellepitope genes, namely EAST-6189-228, Ag85A369-405, CFP10162-207 and Ag85B420-459 which come from the mycobacterium tuberculosis antigen are inserted into an HSP65 full-length gene. The invention alsodiscloses application of an ECANS tuberculosis gene vaccine. Through the intramuscular injection of the gene vaccine into an immune mouse, the experiment proves that the vaccine can induce a specificantibody which aims at a plurality of tuberculosis antigens to response, can induce stronger tuberculosis specific killing response, can induce Th1 immune response at the same time, secrete high-level IFN gamma, and is a good vaccine for preventing and treating tuberculosis.

Disclosed are compounds for use in modulating immune responses. More particularly, the present invention discloses oligomeric forms of PD-L2 for use in modulating Th1 immune responses. The compounds of the present invention find utility in a range of Th1-mediated disorders including pathogenic infections and hyperproliferative disorders.

The invention belongs to the biotechnology field, and relates to a vaccine for controlling the persistent infection of hepatitis B virus. According to the invention, a Hansenula polymorpha cell that is heat inactivated and expresses hepatitis B surface antigen is adopted as the hepatitis B vaccine, wherein the HBsAg is an antigen part of the vaccine and the Hansenula polymorpha cell is an adjuvant part of the vaccine. Animal immunity experiment shows that: the vaccine can induce the aggregation of immune cells to the spleen, promote the maturation of DCs, and both induce Th1 immune response and enhance Th2 immune response in mice, including total IgG, IgG1, IgG2a, specific CTL activity, and the production ability of antigen-specific IFN-gama. The invention can make up for the deficiency of the impossibility of inducing Th1 immune response for traditional vaccines that take aluminium hydroxide as an adjuvant, and is helpful to the control of the persistent infection of hepatitis B virus.

Disclosed in the present invention are a use as an immune enhancer of phytosphingosine-1-phosphate (P1P), O-cyclic P1P (cP1P), N-acetylphytosphingosine-1-phosphate (NAPS-1-P), and pharmaceutically acceptable salts thereof, and a pharmaceutical composition or vaccine for treating dementia, comprising such substance on the basis of a neuronal cell death inhibitory effect. The substance according to the present invention exhibits an effect of enhancing Th2 immune response and inhibiting Th1 immune response and has an effect of protecting neurons as well, and thus can be useful as an immune enhancer to help the production of antibodies for the development of a dementia vaccine, as well as an agent for preventing or treating dementia.

The invention discloses a tuberculosis mucosa gene vaccine assembled by using a chitosan oligosaccharide delivery system. The vaccine is formed by copolymerizing, crosslinking and compounding a chitosan oligosaccharide and a tuberculosis antigen encoding plasmid; a full-length gene of a heat shock protein HSP65 derived from a mycobacterium tuberculosis H37Rv strain is inserted into the tuberculosis antigen encoding plasmid; and four T cell epitope genes, namely, ESAT-6189-228, Ag85A369-405, CFP10162-207 and Ag85B420-459 derived from the mycobacterium tuberculosis H37Rv strain are inserted into the HSP65 full-length gene. The invention further discloses a preparation method and an application of the tuberculosis mucosa gene vaccine. The tuberculosis mucosa gene vaccine disclosed by the invention can be used for inducing tuberculosis specific serum antibodies and systemic Th1 immune response, can be used for inducing lung mucosa locally-enhanced tuberculosis specific secretion type SIgA and IFNgama+Th1 response, and has a remarkably superior effect to that of a naked pECANS gene vaccine.